Boeing Q3 2026: revenue up 3.9% to $24.2B, but a $252M lab-sale gain made most of its $354M operating profit

Boeing's third quarter of 2026 (the three months to September 30) looks like a turnaround at first glance: revenue rose 3.9% to $24,188 million, the company earned $354 million from operations against a $4,781 million operating loss a year earlier, and the net loss attributable to shareholders shrank to $116 million from $5,337 million. Most of that swing is the comparison, not the quarter. A year ago Boeing's commercial airplane unit took a large charge on the 777X program; this year there was no such charge, and a $252 million one-time gain on the sale of HRL Laboratories accounts for most of the operating profit that remains. The commercial airplane business itself lost more money per dollar of sales than it did in the second quarter.

This analysis is written from Boeing's earnings release (Exhibit 99.1 to its 8-K filed October 27, 2026). The full 10-Q has not been filed yet, so the program-by-program cost detail, the size of the 777X charge in the year-ago quarter and any update on fixed-price defense programs such as VC-25B are not available here.

The quarter in numbers

Operating margin is the share of revenue left after the costs of running the business, before interest and tax. "Core" figures are Boeing's own non-GAAP measures: they strip out the gap between pension costs as accounting rules measure them and pension costs charged to government contracts (the "FAS/CAS service cost adjustment"), plus non-operating pension items. Free cash flow is operating cash flow minus spending on plants and equipment. The release gives backlog only for the current quarter end and December 31, 2025, so there is no year-ago backlog figure in the table.

Commercial Airplanes: more planes, worse margin

Boeing Commercial Airplanes (BCA) delivered 161 airplanes, one more than a year ago, but revenue fell 3% to $10,720 million and the segment lost $697 million, a −6.5% margin. Boeing gives three reasons: "less favorable delivery mix, higher projected costs associated with future production rate adjustments and higher estimated supply chain costs."

The mix point is visible in the delivery table. Widebodies, which sell for far more per aircraft than a 737, fell back:

The year-over-year comparison of the loss ($697 million versus $5,353 million) means little: the release says the Q3 2025 margin "was impacted by a charge on the 777X program." The more useful comparison is with the previous quarter, when BCA lost $322 million at a −2.7% margin on 171 deliveries. Deliveries fell by ten, every widebody program but the 767 delivered fewer airplanes, and the margin more than doubled its deficit. Higher projected costs for future rate changes is an estimate revision, the kind of item that tends to show up again if production plans move.

On the operational side, the 737 "continues to progress toward stabilized production of 47 per month," the 787 "remains stable at a production rate of 8 per month," and the 777X "remains on track for first delivery in 2027." The 737-7 received amended type certification from the FAA in the quarter and the 737-10 followed in October. BCA booked 300 net orders (Turkish Airlines, Ethiopian Airlines and Lufthansa among them) and ended with a record backlog of $611.8 billion and more than 6,300 airplanes.

Defense, Space & Security: a gain did most of the work

Defense, Space & Security (BDS) revenue rose 15% to $7,935 million "driven by higher volume," and operating earnings jumped to $492 million (6.2% margin) from $114 million. Boeing says the margin "primarily reflects a $252 million gain on the HRL Laboratories sale and improved operational performance." Take the gain out and BDS earned about $240 million, roughly a 3.0% margin. That is better than the $15 million loss BDS posted in Q2 2026, when a $280 million charge on VC-25B (the Air Force One replacement) hit, but still thin for a defense contractor.

The quarter's biggest defense news is not in the numbers: the U.S. Navy selected Boeing to design, build and deliver the F/A-XX next-generation fighter. Boeing says that order "is not included in backlog pending completion of the source selection and evaluation review process." BDS also won a seven-year contract to expand PAC-3 missile seeker production, and its backlog reached a record $100.5 billion, 23% of it from customers outside the U.S.

Global Services: the steady earner

Global Services (BGS), which sells parts, maintenance and support, grew revenue 4% to $5,574 million and operating earnings 9% to $1,019 million, an 18.3% margin, up from 17.5% on "favorable volume and mix." Its $1,019 million of operating earnings compares with a combined $205 million loss at the other two segments. Backlog was $32.7 billion.

Below the operating line

Interest and debt expense fell 17.4% to $573 million from $694 million, the payoff from repaying debt: total debt is $45.9 billion, down from $54.1 billion at the end of 2025 ($8,415 million of repayments in the first nine months). "Other income, net" fell to $96 million from $276 million; the non-GAAP reconciliation shows part of that is non-operating pension items swinging from $42 million of income to $76 million of expense. The release does not break out the rest. The pre-tax loss was $123 million, a $7 million tax benefit left a net loss of $116 million, and after $87 million of dividends accumulated on the mandatory convertible preferred stock, the loss per share was $0.26.

What the headline numbers hide

• One-off gain in this year, one-off charge in last year. The $5.1 billion operating swing is almost entirely the absence of the Q3 2025 777X charge. Within this quarter's $354 million operating profit, the $252 million HRL Laboratories gain is not repeatable; without it, operating earnings were about $102 million and core operating earnings (Boeing's non-GAAP measure, which still includes the gain) would have been a loss of about $48 million. The pre-tax loss would have been about $375 million instead of $123 million.
• GAAP vs adjusted. Boeing's core loss per share of $0.34 is worse than the GAAP loss of $0.26, because core excludes a $150 million pension cost credit (the FAS/CAS adjustment) that flatters the GAAP line. The gap is pension accounting, not an excluded business cost.
• Cash looks better than profit, for a reason that reverses. Operating cash flow was $1,496 million against a $116 million net loss, even after about $0.7 billion of Department of Justice settlement payments, which Boeing attributes to "working capital timing." Over nine months, customer advances and progress billings added $8,113 million of cash while inventories absorbed $6,733 million. Advances are customer prepayments for airplanes still to be built; that cash unwinds as the aircraft deliver. Inventory reached $90,948 million, up 7.4% since December, and billed plus unbilled receivables rose 18% to $14,248 million, faster than nine-month revenue growth of 8%.
• Spending on plants is rising. Capital spending was $1,032 million in the quarter and $3,040 million in nine months (versus $1,986 million a year earlier), mainly in Charleston and St. Louis. Nine-month free cash flow is still negative at −$359 million.
• More shares, not fewer. Diluted weighted-average shares rose 4.3% to 792.7 million. Boeing does not buy back stock (no repurchases appear in the cash flow statement) and pays no common dividend; it paid $259 million of dividends on its convertible preferred stock in the first nine months (the release gives this cash figure only year-to-date), and it issued $1,275 million of treasury shares to fund 401(k) contributions over the same period. The higher share count makes each dollar of future profit worth slightly less per share.
• No guidance to check against. The release gives no financial guidance for the fourth quarter or full year.

On balance the quarter is flattered: the HRL Laboratories gain supplied $252 million of the $354 million operating profit, and the year-over-year improvement comes from last year's 777X charge not recurring rather than from better results at Commercial Airplanes, whose margin got worse.

Takeaway: Strip out the HRL gain and Boeing earned about $102 million from operations on $24.2 billion of revenue, roughly break-even, the same place it was in Q2. What changed this quarter is outside the income statement: the 737-7 and 737-10 are certified, F/A-XX is won, and backlog is a record $745 billion. Whether those turn into profit depends on Commercial Airplanes, which just moved the wrong way, to a −6.5% margin on fewer widebody deliveries and higher cost estimates.

Did last time's read hold up?

Our Q2 2026 report listed five things to watch. 737-7 and 737-10 certification in 2026: done, with the 737-7 certified in the quarter and the 737-10 in October. That should release the roughly 40 finished aircraft Q2's 10-Q said were parked waiting for it, though the release does not say how many were delivered. 777-9 first delivery in 2027: still "on track." Capital spending above 2025: confirmed, $3,040 million in nine months versus $1,986 million, and nine-month free cash flow is still negative. VC-25B contract reset in Q3: the release does not mention it; that has to wait for the 10-Q. FAA production certification of the new 737 line: not mentioned either. Our Q2 view that segment earnings could not cover interest and corporate costs still holds once the one-off gain is removed: segment earnings excluding the gain were about $562 million, against $573 million of interest and $610 million of unallocated costs.

Outlook

Boeing gives no financial guidance in the release. The commitments it does make are operational: stabilizing the 737 at 47 a month, holding the 787 at 8 a month, and first 777X delivery in 2027. For the next quarter, three figures will show whether this one was a pause or a trend: BCA's margin (does −6.5% improve once newly certified 737-7s and -10s deliver from inventory, or do cost estimates keep rising), widebody deliveries (787 and 777 fell both year over year and quarter over quarter), and BDS earnings without one-off gains. The 10-Q, due in the coming days, should also say whether VC-25B or other fixed-price defense programs needed further charges. Our read: the order book and certifications reduce the risk around Boeing's revenue for years ahead, but profit is still waiting on the commercial factory, and this quarter that factory's economics got worse, not better.